Visceral adiposity index in patients with coronary artery disease, obesity and type 2 diabetes

Aim. To assess visceral adiposity index (VAI) in patients with coronary artery disease (CAD) and overweight or obesity, as well as to determine its relationship with lipid and carbohydrate metabolism parameters and inflammatory markers, depending on the presence of carbohydrate metabolism disorders (CMD).

Material and methods. The study included 95 patients with CAD and overweight (body mass index (BMI) >25 kg/m²) or obesity (BMI >30 kg/m²), of which 59 patients had type 2 diabetes (T2D) and 36 were without CMD. All patients were assessed for obesity; VAI was calculated. Following laboratory parameters were evaluated: glucose, glycated hemoglobin, C-reactive protein, adiponectin, lipid panel. In patients without history of CMD, an oral glucose tolerance test was performed.

Results. Compared with patients without CMD, subjects with T2D had significantly higher values of BMI, waist circumference, as well as the body fat percentage, area and volume of visceral adipose tissue estimated by computed tomography. Analysis of lipid profile, C-reactive protein and adiponectin levels did not reveal significant differences between the groups. VAI also did not significantly differ in both groups. VAI had the most correlations with clinical and metabolic parameters in both patients with T2D and without CMD. Other methods for assessing obesity were less correlated with laboratory parameters in both groups. Only VAI significantly correlated with adiponectin in both groups.

Conclusion. The obtained correlations between VAI and clinical and metabolic parameters confirm the practicability of using it to determine adipose tissue dysfunction in patients with/without CMD. The effect of increased VAI on the cardiovascular risk in high-risk patients requires further study.

1. Muromtseva GA, Kontsevaya AV, Konstantinov VV, et al. The prevalence of non-infectious diseases risk factors in russian population in 2012-2013 years. The results of ECVD-RF. Cardiovascular Therapy and Prevention. 2014;13(6):4-11. (In Russ.) doi:10.15829/1728-8800-2014-6-4-11.

2. Flegal KM, Kit BK, Orpana H, et al. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309(1):71-82. doi:10.1001/jama.2012.113905.

3. Chrysant SG, Chrysant GS. The single use of body mass index for the obesity paradox is misleading and should be used in conjunction with other obesity indices, Postgraduate Medicine, 131:2, 96-102. doi:10.1080/00325481.2019.1568019.

4. Brel NK, Kokov AN, Gruzdeva OV. Advantages and disadvantages of different methods for diagnosis of visceral obesity. Obesity and Metabolism. 2018;15(4):3-8. (In Russ.) doi:10.14341/OMET9510.

5. Amato MC, Giordano C, Galia M, et al. Visceral Adiposity Index A reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33(4):920-2. doi:10.2337/dc09-1825.

6. Libis RA, Isaeva EN. Opportunities for the use of visceral obesity index in metabolic syndrome diagnostics and prognosis of its complication risk. Russian Journal of Cardiology. 2014;(9):48-53. (In Russ.) doi:10.15829/1560-4071-2014-9-48-53.

7. Kouli G-M, Panagiotakos DB, Kyrou I, et al. Visceral adiposity index and 10-year Cardiovascular Disease incidence: the ATTICA Study. Nutrition, Metabolism and Cardiovascular Diseases. 2017 Jul [cited 2019 Jan 25];27(10). doi:10.1016/j.numecd.2017.06.015.

8. Amato MC, Pizzolanti G, Torregrossa V, et al. Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes. PLoS One. 2014 Mar [cited 2019 Jan 28];9(3):e91969. doi:10.1371/journal.pone.0091969.

9. Dedov II, Shestakova MV, Mayorov AY, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AY. 8th edition. Diabetes mellitus. 2017;20(1S):1-121. (In Russ.) doi:10.14341/DM20171S8.

10. Arutyunov GP, Babak SL, Vasyuk YuA, et al. Diagnosis, treatment, prevention of obesity and its associated diseases (national clinical guidelines), 2017. (In Russ.) https://scardio.ru/content/Guidelines/project/Ozhirenie_klin_rek_proekt.pdf.

11. Ezhov MV, Sergienko IV, Kuharchuk VV, et al. Diagnosis and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian guidelines VI revision. Atherosclerosis and Dyslipidemia. 2017;3:5-22. (In Russ.)

12. Wanderley Rocha DR, Jorge AR, Braulio VB, et al. Visceral adiposity measurements, metabolic and inflammatory profile in obese patients with and without type 2 diabetes mellitus: a crosssectional analysis. Curr Diabetes Rev. 2017;13(1):11-8. doi:10.2174/1573399812666151015115924.

13. Bastien M, Poirier P, Lemieux I, et al. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis. 2014;56(4):369-81. doi:10.1016/j.pcad.2013.10.016.

14. Faraj M, Lavoie ME, Messier L, et al. Reduction in serum apoB is associated with reduced inflammation and insulin resistance in post-menopausal women: A MONET study. Atherosclerosis. 2010;211(2):682-8. doi:10.1016/j.atherosclerosis.2010.04.012.

15. Sinitsky MY, Ponasenko AV, Gruzdeva OV. Genetic profile and secretome of adipocytes from visceral and subcutaneous adipose tissue in patients with cardiovascular diseases. Kompleksnye problemy serdečno-sosudistyh zabolevanij. 2017;6(3):155-65. (In Russ.) doi:10.17802/2306-1278-2017-6-3-155-165.